Table II.
Clinical characteristics of the patients with breast cancer (n=111).
| Characteristics | No. of patients |
|---|---|
| Age (years) | |
| Mean, 62.3±13.8 | |
| Range, 27-93 | |
| Primary tumora | |
| T1 | 30 |
| T2-T4 | 81 |
| Stage groupinga | |
| II | 88 |
| III | 23 |
| Molecular subtypes | |
| Luminal A likeb | 42 |
| Luminal B like | 34 |
| Luminal-HER2 | 7 |
| HER2 | 12 |
| TNBC | 16 |
| ER | |
| Positive | 83 |
| Negative | 28 |
| PgR | |
| Positive | 72 |
| Negative | 39 |
| HER2 | |
| Positive | 20 |
| Negative | 91 |
| Ki67 | |
| <30% | 68 |
| ≤30% | 43 |
| Nuclear gradea | |
| 1 | 24 |
| 2 | 45 |
| 3 | 42 |
| Histological classificationc | |
| Invasive ductal carcinoma (total) | 82 |
| Special (total) | 29 |
| Mucinous carcinoma | 4 |
| Medullary carcinoma | 1 |
| Invasive lobular carcinoma | 16 |
| Apocrine carcinoma | 2 |
| Spindle cell carcinoma | 2 |
| Invasive micropapillary carcinoma | 1 |
| Carcinoma with neuroendocrine features | 3 |
a
The grade of the tumor and stages were defined according to the UICC (TNM) classification.
b
Luminal A like were defined as ER+, PgR >20%, HER2− and Ki67 <30%.
c
The classification were defined according to the Japanese Breast Cancer Society (17th edition) (17). ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2.